Insilico Medicine’s AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy Post author: Post published:April 14, 2024 Post category:uncategorized In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances. You Might Also Like How public forests in the U.S. nourish and heal millions November 26, 2024 AI shows promise for predicting embryonic health without invasive testing October 30, 2024 New approach enhances radiation treatment for lung cancer brain metastases October 4, 2024